Vaccine

Biochips Market worth $21.36 billion by 2030 with 8.8% CAGR | MarketsandMarkets™

DELRAY BEACH, Fla., Nov. 24, 2025 /PRNewswire/ -- The global biochips market, valued at US$12.97 billion in 2024, stood at US$14.01…

2 weeks ago

CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2025 and Provides Business Updates

German Federal Cartel Office clearance obtained for the planned BioNTech - CureVac transaction announced on June 12, 2025, marking an…

2 weeks ago

Medicus Pharma Ltd. Explore Novel Treatment Innovations that may Revolutionize Treatments for Prostate and Skin Cancers

PHILADELPHIA, Nov. 24, 2025 (GLOBE NEWSWIRE) -- November is Men’s Health Awareness Month, a time to spotlight the latest medical…

2 weeks ago

ProMIS Neurosciences Announces Reverse Stock Split

Cambridge, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for…

2 weeks ago

Cidara Therapeutics Reaches Target Enrollment of Phase 3 ANCHOR Trial Evaluating CD388 for Prevention of Seasonal Influenza in High-Risk Populations

Target enrollment of 6,000 participants completed in the Northern Hemisphere Planned interim analysis in Q1 2026 will determine potential need…

2 weeks ago

Beat the End-of-Year Healthcare Rush with FSA- and HSA-eligible Telehealth at FSA Store® and HSA Store®

Take advantage of special savings on telehealth services from BetterHelp, Bilt Labs, Daybreak, and MEDVi–and digital health from OURA–when you…

3 weeks ago

Moderna Secures $1.5 Billion Five-Year Credit Facility from Ares Management

Non-dilutive financing from premier lender bolsters strong balance sheet and provides increased flexibilityCompany reiterates 2025 financial guidance provided on 3Q25…

3 weeks ago

Moderna Secures $1.5 Billion Five-Year Credit Facility from Ares Management

Non-dilutive financing from premier lender bolsters strong balance sheet and provides increased flexibilityCompany reiterates 2025 financial guidance provided on 3Q25…

3 weeks ago

Moderna Analyst Day Highlights Pipeline Progress and Business Strategy Updates

Announces three-year business strategy and commercial growth drivers, targeting up to 10% revenue growth in 2026Expects to expand seasonal vaccine…

3 weeks ago

Moderna Analyst Day Highlights Pipeline Progress and Business Strategy Updates

Announces three-year business strategy and commercial growth drivers, targeting up to 10% revenue growth in 2026Expects to expand seasonal vaccine…

3 weeks ago